A Study of Single Doses to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of Nebulised GSK3008348 in Idiopathic Pulmonary Fibrosis Patients, Using Positron Emission Tomography (PET) Imaging
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs GSK 3008348 (Primary) ; GSK 2634673F
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 02 Oct 2017 Planned End Date changed from 10 Jan 2019 to 21 Dec 2018.
- 02 Oct 2017 Planned primary completion date changed from 10 Jan 2019 to 21 Dec 2018.
- 27 Jul 2017 Planned End Date changed from 28 Dec 2018 to 10 Jan 2019.